KNTPF (Kintor Pharmaceutical) Interest Expense: $-0.55 Mil (TTM As of Dec. 2025)


KNTPF Kintor Pharmaceutical Ltd KNTPF
24 GF Score
Price $0.25
! 3 Warning Signs
View Full Analysis

What is Kintor Pharmaceutical Interest Expense?

Kintor Pharmaceutical KNTPF 24 Interest Expense is $-0.55 Mil as of Dec. 2025. GuruFocus rates KNTPF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kintor Pharmaceutical's interest expense for the six months ended in Dec. 2025 was $ -0.24 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.55 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kintor Pharmaceutical's Operating Income for the six months ended in Dec. 2025 was $ -13.08 Mil. Kintor Pharmaceutical's Interest Expense for the six months ended in Dec. 2025 was $ -0.24 Mil. Kintor Pharmaceutical did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kintor Pharmaceutical  (OTCPK:KNTPF) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kintor Pharmaceutical's Interest Expense for the six months ended in Dec. 2025 was $-0.24 Mil. Its Operating Income for the six months ended in Dec. 2025 was $-13.08 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was $0.14 Mil.

Kintor Pharmaceutical's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Kintor Pharmaceutical did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Kintor Pharmaceutical Interest Expense Historical Data

* Premium members only.

The historical data trend for Kintor Pharmaceutical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kintor Pharmaceutical Interest Expense Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.39 -1.17 -1.36 -1.27 -0.56

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -0.72 -0.56 -0.31 -0.24
KNTPF
24GF Score
Kintor Pharmaceutical Ltd KNTPF
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kintor Pharmaceutical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.55 Mil mean?
Kintor Pharmaceutical (KNTPF) has a Interest Expense of $-0.55 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kintor Pharmaceutical and its competitors.
Is Kintor Pharmaceutical's Interest Expense too high?
Kintor Pharmaceutical's current Interest Expense is $-0.55 Mil. Overall, Kintor Pharmaceutical has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Interest Expense compare to VRTX and REGN?
Kintor Pharmaceutical's Interest Expense of $-0.55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kintor Pharmaceutical and its competitors. Kintor Pharmaceutical's current Interest Expense is $-0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Interest Expense of $-0.55 Mil. The current Interest Expense is $-0.55 Mil. Kintor Pharmaceutical's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Interest Expense is $-0.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kintor Pharmaceutical Business Description

Other Exchanges 09939:Hong Kong
Address No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
24GF Score

Get the complete analysis for KNTPF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price